Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

680
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
680
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

574
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
574
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.7K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.7K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

1.1K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.1K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

1.2K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recommendations on the Diagnosis and Treatment of Tuberculosis Infection: SEPAR/SEIMC/Spanish Ministry of Health Consensus Statement.

Enfermedades infecciosas y microbiologia clinica (English ed.)·2026
Same author

Risk of tuberculosis infection according to exposure time and other factors of contacts and their index cases.

Enfermedades infecciosas y microbiologia clinica (English ed.)·2026
Same author

Fourth-generation chemiluminescence QuantiFERON-TB Plus assay <i>versus</i> T-SPOT.TB semi-automated assay: a case for the use of both assays in immunosuppressed patients.

ERJ open research·2026
Same author

In-channel mediastinal cryobiopsy (C-Cryo-EBUS): an international multicenter study of feasibility, safety, and reproducibility.

The European respiratory journal·2026
Same author

Mycobacterium cajalii sp. nov., a novel scotochromogenic rapid-growing nontuberculous mycobacterial species closely related to Mycobacterium servetii.

Antonie van Leeuwenhoek·2026
Same author

Innovations in the diagnosis of tuberculosis infection in prisons.

Revista espanola de sanidad penitenciaria·2026
Same journal

The epidemiological burden and societal cost of 14 respiratory conditions in the World Health Organization European region: systematic evidence map and economic analysis.

ERJ open research·2026
Same journal

Menthol inhalation relieves dyspnoea through the brain.

ERJ open research·2026
Same journal

Understanding the perceptions and experiences of adults with early-onset neuromuscular disorders using noninvasive ventilation in making healthcare decisions.

ERJ open research·2026
Same journal

Exploring glucocorticoid receptor signalling in lymphangioleiomyomatosis.

ERJ open research·2026
Same journal

Senescence intensifies bleomycin-induced injury in idiopathic pulmonary fibrosis lung epithelial cells.

ERJ open research·2026
Same journal

Absolute and relative intensity of physical activity after lung cancer surgery.

ERJ open research·2026
See all related articles

Related Experiment Video

Updated: Feb 26, 2026

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

82.1K

Rifampicin-resistant tuberculosis in Spain.

José-María García-García1, Teresa Rodrigo-Sanz1, José-Antonio Gullón-Blanco2

  • 1Tuberculosis Research Programme (PII-TB), SEPAR (Spanish Society of Pneumology and Thoracic Surgery), Barcelona, Spain.

ERJ Open Research
|February 25, 2026
PubMed
Summary
This summary is machine-generated.

This study analyzed characteristics of multidrug-resistant tuberculosis (MDR-TB) patients in Spain, finding successful outcomes in 88.3% with expert-guided treatment. Comprehension difficulties and pre-extensively drug-resistant tuberculosis (pre-XDR-TB) were linked to lower success rates.

More Related Videos

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.7K
Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples
06:07

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples

Published on: June 6, 2025

1.4K

Related Experiment Videos

Last Updated: Feb 26, 2026

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test
08:10

Diagnosing Pulmonary Tuberculosis with the Xpert MTB/RIF Test

Published on: April 9, 2012

82.1K
The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis
23:06

The MODS method for diagnosis of tuberculosis and multidrug resistant tuberculosis

Published on: August 11, 2008

19.7K
Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples
06:07

Matrix-based DNA Extraction for Targeted Next-Generation Sequencing on Decontaminated Sputum Samples

Published on: June 6, 2025

1.4K

Area of Science:

  • Infectious Diseases
  • Public Health
  • Clinical Medicine

Background:

  • Tuberculosis (TB) remains a global health challenge, with drug-resistant forms posing significant treatment hurdles.
  • Rifampicin-resistance (RR-TB) and multidrug-resistance (MDR-TB) require complex, individualized treatment regimens.
  • Understanding patient characteristics and treatment outcomes is crucial for optimizing TB care in Spain.

Purpose of the Study:

  • To analyze the characteristics of patients with rifampicin-resistant tuberculosis (RR-TB) in Spain.
  • To evaluate treatment regimens, challenges, and outcomes in a cohort of drug-resistant TB patients.
  • To identify factors associated with successful treatment outcomes in this population.

Main Methods:

  • An ambispective observational study was conducted on a multicentre cohort of TB patients diagnosed between January 2019 and July 2023.
  • Data collected included patient demographics, TB history, HIV status, drug resistance profiles (RR-TB, MDR-TB, pre-XDR-TB, XDR-TB), and treatment details.
  • Treatment outcomes were assessed, and factors influencing success were analyzed using statistical methods.

Main Results:

  • A cohort of 94 patients was analyzed, with 88.3% having pulmonary TB. The majority were male (71.3%), foreign-born (66.0%), and had previously treated TB (25.5%).
  • Drug resistance patterns included RR-TB (9 patients), MDR-TB (75 patients), pre-XDR-TB (9 patients), and XDR-TB (1 patient).
  • Successful treatment outcomes (cured or completed) were achieved in 88.3% of patients. Multidrug-resistant tuberculosis (MDR-TB) and absence of treatment comprehension difficulties were associated with higher success rates (OR 10.61).

Conclusions:

  • Most patients with drug-resistant TB in Spain achieved successful outcomes with expert-guided, individualized regimens.
  • Patients with pre-extensively drug-resistant tuberculosis (pre-XDR-TB) and those experiencing treatment comprehension difficulties had significantly lower success rates.
  • Addressing treatment adherence and ensuring clear communication are vital for improving outcomes in complex TB cases.